Copenhagen, Denmark—Patients with platinum-refractory, recurrent head and neck squamous cell carcinoma (HNSCC) derive a significant overall survival (OS) benefit from treatment with the checkpoint inhibitor nivolumab relative to conventional alternatives, according to results of a Phase III trial.
Nivolumab (Opdivo, Bristol-Myers Squibb) “doubled the time to deterioration for most functional domains, prolonging the time that patients were without symptoms,” reported Kevin